克罗辛通过减少BIRC5表达来增强人类乳腺癌细胞对帕克利塔塞尔的敏感性
Yunhao Jia1, Han Yang2, Jinsong Yu3,4
1Department of General Surgery, Nanyang First People's Hospital Affiliated to Henan University, Nanyang, China.
Chemical biology & drug design
|April 25, 2024
概括
克罗辛是一种沙夫兰化合物,通过减少BIRC5表达,克服PTX耐药性和改善患者生存结果,增强了对乳腺癌的帕克利塔塞尔 (PTX) 疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 帕克利塔塞尔 (PTX) 是乳腺癌的主要化疗方法,但耐药性限制了其疗效.
- 沙夫兰中的克罗辛具有抗癌特性,但其在PTX耐药性中的作用尚未被探索.
研究的目的:
- 为了研究克罗辛对乳腺癌中帕克利塔塞尔 (PTX) 耐药性的作用.
- 为了确定参与克服PTX耐药性的crocin的分子标.
主要方法:
- 进行了细胞活力 (CCK-8) 和亡 (TUNEL) 试验.
- 生物信息数据库 (HERB,GEPIA) 确定了crocin和乳腺癌的目标.
- 含有5 (BIRC5) 表达的百科病毒抑制细胞灭亡重复的抑制剂通过qRT-PCR和西方 blot.被分析.
- 使用Kaplan-Meier绘图器和PrognoScan进行的生存分析.
主要成果:
- 克罗辛增强了PTX诱导的亡,并降低了乳腺癌细胞 (MCF-7,MCF-7/PTX) 的活力.
- BIRC5被确定为一个关键的目标;克罗辛抑制了它的表达.
- BIRC5在乳腺癌中过度表达,并与生存率低下有关.
- BIRC5的枯竭使细胞对PTX敏感,而其过度表达则抵消了crocin的作用.
结论:
- 克罗辛使乳腺癌细胞对PTX敏感,部分通过抑制BIRC5表达.
- 准BIRC5代表了在乳腺癌治疗中克服PTX耐药性的潜在策略.
更多相关视频
相关概念视频
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


